Tevogen Bio to Relocate R&D Center Employees to Expanded Warren, NJ Headquarters by June 2025
Tevogen Bio Holdings Inc. has announced plans to relocate employees from its Philadelphia research and development center to its expanded principal executive offices in Warren, New Jersey. This move follows the expiration of the current lease in Philadelphia in June 2025. The relocation comes after Tevogen Bio Inc., a subsidiary of Tevogen Bio Holdings, amended its lease to double the office space at the New Jersey location and extend the lease term until February 2033.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tevogen Bio Holdings Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-013396), on June 03, 2025, and is solely responsible for the information contained therein.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。